Eli Lilly China

Our history in China can be traced back to early 20thCentury. The company set up its first oversea office in Shanghai in 1918 which was Lilly’s first step into its global presence. After years of baptism, Lilly returned to China in 1993. Over the past 20+ years, adhered to the principle of “In China, For China”, Lilly has been forging ahead in developing the business in China. The Lilly products take leading roles in many therapeutic areas including endocrine, central nervous system and oncology, etc. The company’s innovative medicines like Prozac®, Zyprexa®, Cymbalta®, Straterra®, Gemzar®, Alimta®, Evista ®, Forteo®, Cialis®, Humalog®(insulin lispro)and Tradjenta® are widely used in the medical practices in China. While saving lives and improving patients’ life quality, the Lilly products also provide the healthcare professionals and the medical system with more valuable solutions to reduce the medical cost. The core value of Integrity, Excellence and Respect for People guide Lilly in all that we do, it is same in China as in the entire globe. In China, Lilly is determined to fulfill the integrity of corporate citizenship with the philosophy of In China, For China to provide the newest innovative medicines of highest quality to the patients and their families, saving lives and improving the quality of living. By initiating and implementing the diverse public educational programs, Lilly spare no effort to deliver the disease information and promote health knowledge for the sake of improving people’s life quality. In recognition of Lilly’s contributions as a corporate citizen, the company was granted a number of awards including the “Guangming CSR Award”, “Global Top 500 Companies Charity Award”, “National Special CSR Award of China Association of Enterprises”, “Special Contribution Award” by Ministry of Health, “2015 Best Employer in China”, and “Top Employers China 2017”, etc.